---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-036394"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:34:32.135775+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M

## Summary
- Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.
- Total consideration at least $8M and up to $12M from MiMedx for the wound care product.
- NIVIS is an absorbent collagen matrix indicated for wound management and minor bleeding.
- TELA to focus on hernia repair and reconstructive surgery products, including new LIQUIFIX and OviTex configurations.

## SEC filing metadata
- accession: 0001104659-24-036394
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924036394/0001104659-24-036394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924036394/tm249144d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-036394
- JSON: https://secwatch.observer/filing/0001104659-24-036394.json
- Plain text: https://secwatch.observer/filing/0001104659-24-036394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.